FOSUN HEALTH Logo

Kidney Cancer Treatment

catalogue

Kidney Cancer Treatment

Kidney Cancer Treatment

Kidney cancer treatment is organised around two questions rather than one. For localised disease the question is how to remove or control the tumour while leaving as much kidney behind as possible — which is why surveillance, ablation and partial nephrectomy sit alongside removal of the whole organ rather than beneath it. For advanced disease the question is which systemic combination the subtype and risk group support, because stage alone no longer determines the answer.

The route by finding

Because the routes diverge sharply, they are worth setting out together before each is described. The overview page gives the same categories in summary form:

  • Small, confined tumour — active surveillance, thermal ablation, or partial nephrectomy, chosen according to size, position and the patient’s overall condition.
  • Larger but still confined tumour — partial nephrectomy where technically feasible; radical nephrectomy where it is not.
  • Locally advanced tumour — surgery, planned around any venous thrombus, with systemic treatment added where the risk of recurrence is high.
  • Node-positive or metastatic disease — systemic treatment chosen by subtype and risk group, with surgery reserved for selected situations.

One point about sequence deserves emphasis because it is where expectations and guidelines most often diverge. Removing the kidney in metastatic disease — cytoreductive nephrectomy — is no longer automatic. It is now selective: it may be offered to patients with limited spread and good performance status, sometimes before systemic treatment and sometimes after an initial response, while patients with widespread or rapidly progressive disease are usually better served by systemic treatment first. The reasoning is that an operation carries a recovery period during which systemic treatment is delayed, and that delay has to be justified by a benefit the operation is expected to produce.

Active surveillance for a small renal mass

Active surveillance means repeated imaging at a defined interval, with treatment started only if the tumour changes. It is a treatment strategy, not a decision to do nothing, and it rests on two facts: many small kidney tumours grow very slowly, and the risks of intervention — anaesthesia, surgery, a modest loss of kidney function — are real.

  • Who it suits — tumours under about four centimetres, in older patients or those with other significant illnesses, where the chance of the tumour causing harm within the patient’s lifetime is low.
  • Who it does not suit — younger patients, tumours with aggressive features on the scan, and those who would find the uncertainty harder to live with than the treatment.
  • How it is done — imaging every three to six months at first, then at longer intervals if growth is slow. The trigger to act is usually a change in the growth rate rather than a single measurement.

Two things make surveillance work rather than drift. First, the interval and the review date must be written down. An intention to keep an eye on it is not a plan, and the difference between the two is what turns surveillance into a missed window. Second, the decision should be revisited deliberately at each scan rather than left open indefinitely, because a tumour that has begun to grow faster is a reason to change course, not a reason to keep watching.

Preserving the kidney, or removing it

Surgery is the definitive treatment for localised kidney cancer, and the choice between preserving and removing the organ is the central decision. Where both are technically possible, partial nephrectomy — removing the tumour and the margin around it while leaving the healthy kidney in place — is preferred, because it preserves filtering capacity and lowers the long-term risk of kidney failure.

  • Partial nephrectomy — for tumours where the tumour can be completely removed with enough normal kidney left behind. The operation is planned from the scan, so the amount of kidney to be spared is decided in advance. Where the tumour permits, it is performed laparoscopically or with robotic assistance, which shortens recovery.
  • Radical nephrectomy — removal of the whole kidney, used when the tumour is large, centrally placed, or involves structures that cannot be safely separated, and when preserving the organ would risk leaving tumour behind.
  • Complex and locally advanced surgery — tumours extending into the renal vein or the large vein above it, which require a planned approach to the vein and sometimes the involvement of a vascular surgical team.

Two honest points belong in that conversation. First, partial nephrectomy is technically harder and carries a slightly higher chance of complications such as bleeding or a urine leak — a trade-off entered into deliberately, exchanging a little short-term risk for a lower long-term risk of losing kidney function. Second, where preserving the kidney would not allow the tumour to be removed completely, preserving it anyway is not a compromise in the patient's favour; in that situation removing the whole kidney is the safer oncological choice. Which situation applies should be explained by the surgeon in terms of what the scan shows rather than in general terms.

Ablation: destroying the tumour in place

Thermal ablation destroys a small kidney tumour with heat or cold delivered through a needle placed into it under imaging guidance. The two techniques in common use are radiofrequency ablation, which uses heat, and cryoablation, which freezes the tissue.

  • When it is used — small tumours, generally under about three centimetres, in patients who cannot undergo surgery, who have reduced kidney function that argues against an operation, or who have tumours in both kidneys or in a solitary kidney.
  • What it offers — no surgical incision, a short hospital stay and a quicker recovery than an operation.
  • What it costs — a biopsy is generally taken first because the tissue is destroyed rather than examined; follow-up imaging is needed to confirm that the treated area has stopped enhancing; and the chance of the tumour recurring locally is somewhat higher than after surgical removal, which is why surveillance afterwards is not optional.

Because ablation leaves no specimen, a histological diagnosis has to be obtained beforehand; and because the result is confirmed by imaging rather than by pathology, follow-up is arranged more closely than after an operation. Ablation is a good choice in the right situation, but for a patient who can be operated on safely it is not a general substitute for surgery, and the assessment should state which situation applies.

Treatment after surgery

For patients whose tumour has been completely removed but who are at high risk of recurrence, treatment after the operation may be offered. The aim is to reduce the chance of the disease returning, and it applies to a defined group rather than to everyone.

  • Immune checkpoint inhibitor after surgery — offered for high-risk disease that has been completely removed, based on the stage, grade and other features of the specimen. Whether an individual patient is in that group depends on the pathology report rather than on the size of the tumour alone.
  • Who is not in that group — patients whose tumour was small, low grade and entirely confined, where the risk of recurrence is low enough that the benefit of treatment would not outweigh its side effects.
  • What the decision requires — the full pathology report, including subtype, grade and the extent of invasion, because the risk assessment is built from those features.

The question worth asking after an operation is therefore a specific one: on the basis of this specimen, am I in the group for which treatment after surgery has been shown to help? If the answer is yes, the discussion should cover what the treatment involves and what side effects to expect; if the answer is no, it is reasonable to ask what the follow-up plan is instead. What should not happen is a decision made from the tumour size alone, because size is only one input.

Systemic treatment for advanced disease

When kidney cancer has spread or cannot be removed completely, treatment is systemic, and the choice is driven by the histological subtype and the risk group rather than by the stage number alone. Two families of drug are used, often in combination:

  • Immunotherapy combinations — a checkpoint inhibitor paired with another checkpoint inhibitor or with a targeted agent. This is the usual first approach for clear cell tumours in the intermediate and poor risk groups.
  • Targeted agents acting on the tumour’s blood supply — drugs that block the vascular endothelial growth factor pathway, which kidney tumours depend on heavily. These are used as single agents in favourable-risk disease and as partners in combinations.
  • Drugs used after first-line treatment fails — a further targeted agent, a combination of a targeted drug with an mTOR inhibitor, or a HIF-2α inhibitor such as belzutifan, which is also used for tumours arising in von Hippel-Lindau disease.
  • Subtype-specific treatment — papillary and chromophobe tumours follow different regimens from clear cell tumours, and papillary tumours with a MET alteration have a specific targeted option.

Three practical points shape how this is experienced. First, the risk group has to be calculated before the first drug is chosen, which requires the blood results and a performance assessment as well as the stage. Second, which line follows which is a plan rather than a single decision, reviewed as treatment proceeds, because what has already been given constrains what is sensible next. Third, side effects differ meaningfully between the two families, and the choice between combination regimens of similar effectiveness is often made on that basis — fatigue, blood pressure, thyroid function and immune-related effects for one family; diarrhoea, hand and foot reactions and fatigue for the other.

When disease has spread

For disease that has spread beyond the kidney, three questions organise the plan, and all three should be answered explicitly rather than absorbed into a single recommendation:

  • How much disease is there, and where? — limited spread confined to a few sites is treated differently from widespread involvement, and the lungs, bone and liver each raise their own issues.
  • What is the risk group? — the six IMDC factors place the disease in a favourable, intermediate or poor group, which decides whether a combination or a single agent is used first.
  • Does local treatment still have a role? — a kidney that is bleeding, painful or obstructing may need surgery or embolisation for symptom control, and bone disease may need radiotherapy or a bone-protecting drug, all alongside systemic treatment rather than instead of it.

One pattern is worth recognising because it recurs in practice. Bone and brain involvement produce symptoms that are treated in their own right — pain, fracture risk, neurological effects — and those treatments run in parallel with the systemic regimen rather than after it. A written plan should therefore say not only which drugs are being used but what is being done about each site of disease, and what would trigger a change.

How the treatment decision is made

Kidney cancer decisions sit across several disciplines, and the trade-offs are genuine rather than apparent. A review brings these together:

  • Urological surgery — whether the tumour can be removed with the kidney preserved, and how much kidney would remain either way.
  • Interventional radiology — whether ablation is feasible for this tumour in this position, and whether a biopsy is needed first.
  • Medical oncology — which systemic regimen the subtype and risk group support, and in what order.
  • Pathology and imaging — the subtype, the grade, the size, and the extent of any venous or nodal involvement.
  • Kidney function and the patient’s priorities — creatinine and filtration rate on one side; willingness to accept surveillance, an operation or ongoing treatment on the other.

What a written assessment should therefore contain is not a single recommendation but a set: the routes the findings support, the trade-off between them, and the specific findings that would change the answer. That is what makes it usable by a patient deciding whether to travel, and by a treating clinician deciding what to plan.

Frequently Asked Questions

Can a small kidney tumour simply be watched?

Yes, for a defined group of patients, and this is a legitimate treatment strategy rather than a delay. Active surveillance suits tumours under about four centimetres in older patients or those with other significant illnesses, where the chance of the tumour causing harm within the patient’s lifetime is low. It means imaging every three to six months at first, with treatment started if the growth rate changes or the patient prefers to act. It does not suit younger patients or tumours with aggressive features on the scan. What matters is that the interval and the review date are written down, so that watching does not become a missed window.

Will treatment leave me needing dialysis?

For most patients, no — but avoiding that outcome is exactly why partial nephrectomy is preferred whenever it is technically feasible. Two kidneys provide more filtering capacity than the body needs, so losing one is usually tolerated. The risk is higher when kidney function was already reduced, when a large part of the remaining kidney must also be removed, or when the patient has diabetes or long-standing hypertension. This is why creatinine and estimated filtration rate are measured and considered before treatment, and why the choice between preserving and removing the kidney is made from the scan rather than from habit.

What treatment is available if the cancer has spread?

Systemic treatment, organised by the histological subtype and the risk group rather than by stage alone. For clear cell tumours in the intermediate or poor risk groups, an immunotherapy combination is the usual first approach; favourable-risk disease is often treated with a single targeted agent. When the first line stops working, options include a further targeted agent, a targeted drug combined with an mTOR inhibitor, or a HIF-2α inhibitor such as belzutifan. Papillary and chromophobe tumours follow different regimens, and a papillary tumour with a MET alteration has a specific targeted option. Local treatments such as radiotherapy or embolisation are used alongside these for symptoms from individual sites.

Is treatment after surgery always needed?

No — it applies to a defined group, and the decision is made from the pathology report rather than from the size of the tumour alone. Treatment after surgery with an immune checkpoint inhibitor is offered for high-risk disease that has been completely removed, based on the stage, the grade and the extent of invasion described in the specimen. Patients whose tumour was small, low grade and entirely confined are generally not in that group, because the risk of recurrence is low enough that the side effects of treatment would outweigh the benefit. The useful question after an operation is therefore whether this particular specimen places you in the group for which treatment has been shown to help.

Let the subtype and kidney function decide the route

Send the multiphasic CT or MRI as images, the pathology report with the subtype and grade, and recent blood tests including creatinine. Our urological oncology team will return a written assessment within 48 hours of the file being complete, setting out whether preserving the kidney is feasible and which systemic options the subtype supports.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*